Rekvina Laboratories Ltd. to Increase Authorized Capital and Acquire 100% Stake in Radiant Parenterals Limited

Rekvina Laboratories Ltd. has approved an increase in its authorized capital and the acquisition of 100% equity shares of Radiant Parenterals Limited from existing shareholders. The acquisition will be made at a price of ₹ 25 per equity share, for a total consideration of ₹ 4,62,77,500. The consideration will be discharged by issuing 46,27,750 equity shares of Rekvina Laboratories Ltd. on a preferential basis. The proposed transaction is being undertaken on an arm's length basis and is subject to regulatory approvals and the approval of the shareholders of Rekvina Laboratories Ltd.